ClinicalTrials.gg

Sleep Apnea, Obstructive clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,243 studies for Sleep Apnea, Obstructive across more than 10 countries. 475 are recruiting or about to start. 1,802 of them are mainly about Sleep Apnea, Obstructive (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Obesity Hypoventilation Syndrome too: 2,304 studies, 482 open.

ClinicalTrials.gov finds 2,594 studies for Sleep Apnea, Obstructive. How that becomes 2,243 here

This page counts the studies the registry files under Sleep Apnea, Obstructive, and those it files under no condition that list Sleep Apnea, Obstructivethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,594Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −61Filed under a narrower condition, counted on its own pageObesity Hypoventilation Syndrome 61
  3. −41List Sleep Apnea, Obstructive as a condition, but the registry did not file them under itMost often written as “Obstructive Sleep Apnea of Adult” (10), “Obstructive Sleep Apnea of Child” (7), and “Obstructive Sleep Apnea-hypopnea Syndrome” (5). The registry filed them under other conditions only, most often Sleep Apnea Syndromes (15) and Apnea (4).
  4. −249Match it another way211 name it in the title, 4 in a keyword, and 34 by a synonym or other text the search reads.
  5. 2,243The count on this page70 of them list Sleep Apnea, Obstructive in their own words; the registry filed them under no condition.

Status

Completed
1,201
Recruiting
313
Status unknown
275
Not yet recruiting
134
Terminated
128
Withdrawn
91

Phase

Phase 2
127
Phase 3
100
Phase 4
98
Phase 1
61
Early Phase 1
21

Where

United States
753
France
201
Canada
133
China
108
Brazil
102
Taiwan
90

Who develops what

Add Sleep Apnea, Obstructive to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 15 programs from 12 companies, 11 with this as their studies’ main aim; 9 with a live phase 3 study; 6 primary completions in the next 12 months. Compare Shionogi, Amgen and Eli Lilly here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DronabinolRecent, limited
Evidence
  • NCT06146101 · Incannex Healthcare Ltd · Phase 3 · comparator · “Dronabinol” · registered Nov 2023
Jazz Pharmaceuticals15% of its industry studiesUS: off-patent, 1 generic marketed11 study
ModafinilEarlier only
Evidence
  • NCT00620659 · Merck & Co., Inc · Phase 2 · background · “Comparator: modafinil” · registered Jan 2008
  • NCT00086281 · Jazz Pharmaceuticals · Phase 4 · background · “Modafinil (M)” · registered Jun 2004
Teva Pharmaceutical Industries, Ltd.79% of its industry studiesUS: off-patent, 9 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
ribupatide☆ Track1 live phase-3 study: NCT06974851Jiangsu HengRui Medicine Co., Ltd.
maridebart cafraglutide☆ Track2 live phase-3 studies: NCT07225686, NCT07226765Amgen
bofanglutide☆ Track2 live phase-3 studies: NCT07493057, NCT07501832Gan & Lee Pharmaceuticals
ecnoglutide☆ Track2 live phase-3 studies: NCT07387094, NCT07434050Hangzhou Sciwind Biosciences Co., Ltd.
HDM1005☆ Track2 live phase-3 studies: NCT07794397, NCT07787260Huadong Medicine Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 15 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (6)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.ribupatide · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 main aimNCT06974851 A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity — primary endpoint: Percentage Change in AHI from Baseline at Week 52 of Treatment · 140 enrolled
  • 31 Dec 2026 est.sivopixant, Acetazolamide, SASS-001 · Shionogi · Phase 2 registry mapping onlyNCT06776432 Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea — primary endpoint: Primary Endpoint - Change in apnea-hypopnea index (SASS-001 arm vs baseline at Visit 7 polysomnography). Scale is minimum -60 to max 60. Lower scores mean improvement from baseline. · 60 enrolled
  • Apr 2027 est.Dronabinol, Acetazolamide · Incannex Healthcare Ltd · Phase 2 main aimNCT07635563 DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea. — primary endpoint: Change in AHI4 at the end of each treatment period compared to baseline · 120 enrolled

3 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Sleep Apnea, Obstructive studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Diuretics 3 open · Antimuscarinics 2 open · GLP-1 receptor agonists 2 open · Corticosteroids 12 · Stimulants 11

Coming up

158studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger. 52 (17%) take children under 18. 3 (1%) are for women only and 1 (<1%) for men only; 65 (21%) take healthy volunteers.

Recruiting studies that take each age, of 313
AgeWomenMen
1046 (15%)45 (14%)
18227 (73%)225 (72%)
30255 (81%)252 (81%)
40263 (84%)261 (83%)
50263 (84%)262 (84%)
65254 (81%)252 (81%)
75207 (66%)205 (65%)
85164 (52%)162 (52%)

Across all 2,243 studies, recruiting or not: 41% stop at 75 or younger and 26% at 65; 13% take children; 2% are for women only and 3% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Sleep Apnea, Obstructive studies take

Of 47 phase 2 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 26 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 110 mo5–44 · 27 studies——
Phase 226 mo9–46 · 47 studies——
Phase 320 mo17–32 · 27 studies——
Phase 426 mo17–35 · 31 studies—26 mo18–35 · 28 studies
Interventional, no phase27 mo12–50 · 624 studies12 mo3–21 · 116 studies33 mo17–53 · 508 studies
Observational28 mo14–63 · 294 studies18 mo7–93 · 36 studies31 mo16–61 · 258 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered22

Show 17 more

Studies

Recruiting first, then most recently updated. Showing 50 of 2,243. Browse all 2,243 → or search them.